Japanese biopharma Carna Biosciences Inc. and Gilead Sciences Inc., of Foster City, Calif., have signed a $470 million R&D collaboration to develop and commercialize small-molecule compounds in immuno-oncology. Under the agreement, Gilead will license worldwide rights to develop and commercialize inhibitors against an undisclosed immuno-oncology target from Kobe, Japan-based Carna. Additionally, Gilead will have access to Carna's lipid kinase drug discovery platform.
HONG KONG – Two Korean biotech companies, Genexine Inc. and Toolgen Inc., have agreed to merge into a single entity named Toolgenexine Inc., in order to develop novel immunotherapy drugs with gene editing technology.
Japan has become the first country to give approval for Rozlytrek (entrectinib), a drug targeting patients with NTRK fusion gene-positive solid tumors, regardless of the site of disease origin. The Japanese Ministry of Health, Labour and Welfare (MHLW) had granted the drug both orphan drug designation and Sakigake status, which allows the accelerated approval of drugs designated as breakthrough therapies.
HONG KONG – Aiming to accelerate investment in China's science and technology ventures, Shanghai Stock Exchange officially opened a new market earlier this month. The Science and Technology Innovation Board (STIB) launched the Sci-Tech Innovation Board (STAR) to list Chinese companies with high potential, namely tech unicorns from emerging sectors such as biomedicine, AI, IT, advanced equipment, new materials and energy.
HONG KONG – Astrazeneca plc said it will invest $630 million over the next five years in South Korea's health care industry, marking the largest-ever investment by a foreign pharma company in Korea.
HONG KONG – Aiming to accelerate investment in China's science and technology ventures, Shanghai Stock Exchange officially opened a new market earlier this month. The Science and Technology Innovation Board (STIB) launched the Sci-Tech Innovation Board (STAR) to list Chinese companies with high potential, namely tech unicorns from emerging sectors such as biomedicine, AI, IT, advanced equipment, new materials and energy.
Japan has become the first country to give approval for Rozlytrek (entrectinib), a drug targeting patients with NTRK fusion gene-positive solid tumors, regardless of the site of disease origin. The Japanese Ministry of Health, Labour and Welfare (MHLW) had granted the drug both orphan drug designation and Sakigake status, which allows the accelerated approval of drugs designated as breakthrough therapies.
HONG KONG – Astrazeneca plc said it will invest $630 million over the next five years in South Korea's health care industry, marking the largest-ever investment by a foreign pharma company in Korea.
HONG KONG – Swedish biopharma Calliditas Therapeutics AB and Singapore-headquartered pharmaceutical company Everest Medicines II Ltd. agreed to develop and commercialize Nefecon for the treatment of IgA nephropathy in greater China and Singapore in a deal valued at more than $121 million.
